Literature DB >> 17451832

Effect of interferon-lambda on replication of hepatitis B virus in human hepatoma cells.

Seung-Ho Hong1, Okki Cho, Koyngmin Kim, Ho-Joon Shin, Sergei V Kotenko, Sun Park.   

Abstract

The antiviral activity of interferon-lambda (IFN-lambda) against several viruses has been reported, but it has not been investigated whether human IFN-lambda can affect replication of the hepatitis B virus (HBV) in human hepatocyte-derived cells. We found that replication of HBV in a human hepatoma cell line was reduced by approximately 30% following treatment with a high concentration of IFN-lambda. Furthermore, we showed that replication of HBV in another human hepatoma cell line was not suppressed by IFN-lambda. However, these cell lines showed a similar level of transcription for the heterodimeric IFN-lambda receptor and the IFN-lambda-induced antiviral proteins. Our results suggest that the antiviral activity of IFN-lambda against HBV may be limited in human cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17451832     DOI: 10.1016/j.virusres.2007.03.006

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  29 in total

Review 1.  Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.

Authors:  Nicole E Pagliaccetti; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

2.  Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.

Authors:  Barbara Kroczynska; Sonali Joshi; Elizabeth A Eklund; Amit Verma; Sergei V Kotenko; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

3.  IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection.

Authors:  Maureen P Martin; Ying Qi; James J Goedert; Shehnaz K Hussain; Gregory D Kirk; W Keith Hoots; Susan Buchbinder; Mary Carrington; Chloe L Thio
Journal:  J Infect Dis       Date:  2010-10-26       Impact factor: 5.226

4.  Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells.

Authors:  Jiradej Makjaroen; Poorichaya Somparn; Kenneth Hodge; Witthaya Poomipak; Nattiya Hirankarn; Trairak Pisitkun
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

5.  HBV life cycle and novel drug targets.

Authors:  Daniel Grimm; Robert Thimme; Hubert E Blum
Journal:  Hepatol Int       Date:  2011-03-08       Impact factor: 6.047

6.  Chronic hepatitis B and IL28B rs12979860 polymorphism: preliminary study.

Authors:  Özlem Kandemir; Senay Balcı Fidancı; Neslihan Demir; Ayşegül Görür; Lülüfer Tamer
Journal:  Mol Biol Rep       Date:  2013-09-22       Impact factor: 2.316

7.  Antitumor activity of type I and type III interferons in BNL hepatoma model.

Authors:  Walid Abushahba; Murugabaskar Balan; Ismael Castaneda; Yao Yuan; Kenneth Reuhl; Elizabeth Raveche; Andrew de la Torre; Ahmed Lasfar; Sergei V Kotenko
Journal:  Cancer Immunol Immunother       Date:  2010-03-09       Impact factor: 6.968

8.  MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1.

Authors:  Yongkui Li; Jiajia Xie; Xiupeng Xu; Jun Wang; Fang Ao; Yushun Wan; Ying Zhu
Journal:  Protein Cell       Date:  2012-11-12       Impact factor: 14.870

Review 9.  Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments.

Authors:  Ceen-Ming Tang; Tung On Yau; Jun Yu
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1).

Authors:  Yongkui Li; Jiajia Xie; Xiupeng Xu; Li Liu; Yushun Wan; Yingle Liu; Chengliang Zhu; Ying Zhu
Journal:  J Biol Chem       Date:  2013-05-31       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.